Caspian Navigation - Light Background Variant
Newsletter

Caspian Weekly Trade Policy Digest - August 5, 2026

August 5, 2026

Caspian Dinner Series

We're hitting the road!

Caspian is hosting an invitation-only dinner series bringing together customs, trade, and supply chain leaders for candid conversations on the issues shaping global trade today.

We'll be in the NYC and Philly areas in late August and Texas in early September. We're still mapping out the rest of our fall schedule. Let us know what city we should visit next!

Weekly Trade Policy Update

The Pharma Tariffs Are Live

The Bottom Line

Three trade developments caught our attention this week. Section 232 tariffs on patented pharmaceuticals took effect. Imports from companies named in Annex III of Proclamation 11020 now carry rates as high as 100%. The U.K. is the exception at 0%. DHS also added 43 companies to the UFLPA Entity List, putting any importer with ties to them at risk of detention.

Section 232

Section 232 Pharma Tariffs: What You Need to Know

Section 232 tariffs on patented pharmaceuticals and their ingredients took effect July 31. Imports from companies listed in Annex III of Proclamation 11020 now face combined duties of up to 100% under heading 9903.04.60.

The rate depends on the country. The U.K. moved to 0% after its pricing agreement with the U.S. Imports from the European Union, Japan, South Korea, and Switzerland remain at 15%. All other covered companies continue under the temporary zero-duty provision at 9903.04.61 until September 29, when their applicable rates begin. CBP's guidance to the trade carries the full rate table.

Why It Matters

Unlike the February Section 122 surcharge, these Section 232 duties are eligible for drawback. Importers exporting finished pharmaceuticals or re-exporting ingredients may be able to recover duties paid at entry, but the claim depends on having the right records. Keep entry and export records tied together from the first shipment!

All Chapter 29 and 30 pharmaceutical entries must now report one of the new 9903.04 headings, even when no duty is owed. Generic drugs, their ingredients, and products of U.S. origin are excluded.

Sources: CBP guidance to the trade, CSMS #69395344, Proclamation 11020, 91 FR 18183

US-UK Deal

The UK Is Now at 0%

The U.K.'s patented pharmaceutical tariff dropped from 10% to 0% on July 31 after both governments reached a pricing agreement. CBP updated ACE under heading 9903.04.63.

Other countries currently at 15% could follow a similar path if agreements are finalized. For importers, the takeaway is simple: tariff rates are not always static. Landed cost models should account for potential changes.

Sources: Commerce notice, 91 FR 49406, CSMS #69415934

Forced Labor

DHS Adds 43 Companies to the UFLPA Entity List

DHS added 43 companies to the Uyghur Forced Labor Prevention Act Entity List on August 3. Goods tied to those entities are now subject to a rebuttable presumption that they were made with forced labor. CBP can detain a shipment until the importer overcomes that presumption with evidence. Two of the 43 companies appear on two separate sub-lists, and two existing entries were corrected.

The risk extends beyond direct suppliers. If materials in your supply chain trace back to a listed entity, CBP can apply the presumption even if that company is not on your invoice. Review the 43 new names against your vendor and sub-tier supplier records this week.

Source: DHS notice, 91 FR 48913

Other Trade Updates

Van-type trailers: Commerce issued preliminary antidumping findings on van-type trailers from Canada and Mexico and extended provisional measures. Cash deposits now apply where required. USMCA origin does not exempt goods from antidumping duties. (Canada 91 FR 49407, Mexico 91 FR 49416)

Linear hydraulic cylinders: The ITC opened AD/CVD investigations covering imports from Canada, China, India, Mexico, and South Korea. No duties are owed yet; the preliminary vote is scheduled for September 14. (91 FR 49442)

Calendar

Dates That Matter

  • Jul 31: Section 232 pharma tariffs took effect; U.K. rate moved to 0%
  • Aug 3: 43 companies added to the UFLPA Entity List
  • Aug 5: Closed IEEPA refund status conference before Judge Eaton at the Court of International Trade. CAPE Phase 3, which covers finally liquidated entries, is still not open
  • Aug 6: Court of International Trade hearing on class certification for IEEPA refund plaintiffs. Certification would open a recovery path for importers that have not filed suit
  • Sep 14: ITC preliminary vote on linear hydraulic cylinders
  • Sep 29: Section 232 pharma tariffs expand beyond Annex III companies; temporary zero-duty provision at 9903.04.61 ends

Action Items

What Importers Should Do Now

Review your pharmaceutical classifications

Pull your Chapter 29 and 30 entries and match each one to the correct 9903.04 heading. Start with the Annex III companies, which can reach a 100% duty

Screen suppliers against the updated Entity List

Check your direct vendors and sub-tiers before your next shipment

Establish the drawback process now

These duties may be recoverable, but the claim depends on having entry and export records that line up

Model your exposure for September 29

If the temporary zero-duty provision is what you currently file under, calculate landed cost at your real rate before it ends

▸ Reach Out to Caspian to Understand Your Impact

Technology Updates

What's New on Caspian

Open a spreadsheet without leaving Caspian. XLSX and CSV files render right next to the entry they came from.

Forwarded email counts as a document. Send one in and it lands with the invoices and bills of lading for that entry.

Also Shipped This Cycle

  • Units convert on import, no mapping step
  • Edit product details in place
Caspian Trade, Inc.
2261 Market Street
San Francisco, California 94114

Refunds recovered. Compliance handled. Margins protected.

Credentials
SOC 2
ABI
LCB

CBP-Approved ABI Vendor Platform. Licensed customs brokers.

The Bottom Line

You don't know what trade is costing you. We do.

Get your number
Caspian